Optimizing Treatment Strategies for Metastatic NSCLC: Achieving the Best Patient Outcomes  : Episode 9

Jason’s Journey with ALK+ Metatstatic NSCLC

February 19, 2025

Opinion

Video

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with ALK+ non-small cell lung cancer as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN

EP: 1.Robert’s Journey With EGFR+ Metastatic NSCLC

EP: 2.Patient Guidance and Education of EGFR Inhibitor Therapies

EP: 3.Strategies to Managing Cardiotoxic AEs with Osimertinib

EP: 4.Balancing Treatment Benefits and Toxicity: Managing Quality of Life in EGFR+ NSCLC Patients

EP: 5.Strategies of Dose Modifications of Osimertinib and Other EGFR Inhibitors

EP: 6.Management of GI Toxicities in Osimertinib and other EGFR Inhibitors

EP: 7.Importance of Multidisciplinary Team in Managing AEs of EGFR Inhibitors

EP: 8.Comparison of Safety Profiles of EGFR Inhibitors

Now Viewing

EP: 9.Jason’s Journey with ALK+ Metatstatic NSCLC

EP: 10.Patient Education and Guidance on Lorlatinib and Other ALK Inhibitors

EP: 11.Management of Neurotox AEs with Lorlatinib

EP: 12.Management of Hyperlipidemia and Weight Gain with Lorlatinib

EP: 13.Management of GI AEs with ALK Inhibitors

EP: 14.Dose Modifications When Managing Side Effects with ALK Inhibitors

EP: 15.Role of Multidisciplinary Strategies in care of ALK+ NSCLC Patients

EP: 16.Patient Factors in Treatment Selection of ALK Inhibitors

Video content above is prompted by the following:

34-year-old professional rock climber with ALK+ Stage IV metastatic NSCLC, previously healthy with no smoking history.
Persistent lower back pain unresponsive to rest and PT, followed by increased fatigue led to initial doctor visit.
CT scan revealed a left lung mass with lymph node involvement and a small metastasis on the spine; molecular testing confirmed ALK-positive status.
Started on lorlatinib, with manageable GI issues and fatigue as side effects; patient is motivated to return to climbing.

Related Content

Oncology Nurses Provide Patients an Avenue to Supportive Care

Diana Martins-Welch, MD

November 12th 2019

Article

Palliative care is often associated with a patient entering end of life treatment and giving up on their treatment, but that isn't the reality of what id can do for patients. And oncology nurses can help guide patients to the right supportive care for them.

New Findings Could Change the Everyday Treatment of Patients With Advanced Prostate Cancer

Daniel J. George, MD

October 3rd 2019

Article

For patients with advanced prostate cancer, new findings from the CARD trial could change their daily treatment.

Adverse Events of CAR T-Cell Therapy

Sattva S. Neelapu, MD

July 28th 2019

Article

It is crucial for nurses to be aware of adverse events that can occur in patients who are receiving CAR T-cell therapy, explained one expert.

Prostate Cancer Diagnoses Decrease With Lenient Screening Recommendations

MaryBeth Freeman, MPH

May 8th 2019

Article

After the USPSTF advised against prostate cancer screening for all men, there was a decrease in the incidence of the disease.

Hyman B. Muss Discusses the Importance of Nurses in Treating Pregnant Women With Breast Cancer

Hyman B. Muss, MD

March 23rd 2016

Article

Hyman B. Muss, MD, professor of medicine at the University of North Carolina School of Medicine, discusses the vital roles that nurses play when it comes to treating pregnant women with breast cancer.

Kimberly J. Van Zee on Nomograms Helping in DCIS Treatment Decision-Making

Kimberly J. Van Zee, MS, MD, FACS

March 18th 2016

Article

Kimberly J. Van Zee, MS, MD, FACS, attending surgeon at Memorial Sloan Kettering Cancer Center, discusses the institution's newly-developed nomogram that can help women make treatment decisions about ductal carcinoma in situ (DCIS).